On October 22, 2026, Meinian Onehealth Healthcare Holdings Co.,Ltd. (ASX: 002044) announced that Tongyi No. 3 and Tongyi No. 12, persons acting in concert with the company's actual controller Yu Rong, had completed their share reduction plan, selling a combined 20.666 million shares through centralized bidding, representing 0.53% of total share capital. Following the completion of the reduction, the combined shareholding ratio of Yu Rong and his concert parties fell from 17.42% to 16.89%, crossing the 1% equity change threshold.
Just one month earlier, Alibaba-affiliated holding platform Hangzhou Haoyue had wrapped up its three-month share reduction cycle, having cumulatively sold 3% of the company's shares, bringing its stake down to 5.39%. Related entities had already reduced their holdings on multiple previous occasions, and each reduction was carried out at a loss.
On October 15, the company disclosed its earnings forecast for the first three quarters of 2026, projecting net profit attributable to shareholders of 91 million yuan to 100 million yuan, up 75.47% to 92.83% year-on-year, while non-GAAP net profit was expected to reach 80 million yuan to 89 million yuan, surging 554.19% to 627.78% year-on-year.
With profitability recovering on one side and major shareholders continuing to reduce their stakes on the other, what does the future hold for the company?
Alibaba Consortium Exits at Deep Loss; Controlling Shareholder Camp Reduces in Tandem
Looking back, the frequency of share reduction announcements increased markedly in 2025 and 2026. Public records show that between 2020 and 2023, the company disclosed three announcements of shareholders reducing more than 1% of shares. In May and November 2025, the company issued two pre-disclosure announcements regarding share reductions by shareholders holding more than 5%, with shareholder Hangzhou Haoyue Enterprise Management Co., Ltd. and its concert party Hangzhou Xintou Information Technology Co., Ltd. carrying out reductions on two separate occasions, ultimately selling 117 million shares and 64 million shares, representing 3% and 1.63% of total share capital, respectively.
In May 2026, Hangzhou Haoyue once again disclosed a reduction plan, proposing to sell no more than 3% of total share capital within three months. On September 22, the reduction plan was completed, with Hangzhou Haoyue fully executing the planned sale. After completion, the shareholding ratio of the company and its concert party Hangzhou Xintou fell to 5.39%, less than half of the 13.03% held before the initial reduction in early May 2025.
Records show that in 2019, Alibaba made a strategic investment of approximately 4 billion yuan in Meinian Onehealth, at a cost of about 12 yuan per share. In 2024, Alibaba transferred its holdings to Hangzhou Haoyue through a spin-off, making the latter the executing entity for Alibaba-affiliated share reductions. Based on the reduction price ranges disclosed in announcements, all of Alibaba's previous reductions were completed at deep losses.
While industrial capital reduced holdings at a paper loss, the company's actual controller camp also chose to cash out at low levels. In September 2026, the company disclosed a pre-disclosure announcement regarding share reduction by persons acting in concert with the actual controller. Guo Meiling, a person acting in concert with the company's actual controller, planned to reduce her holdings through the fund products Tongyi No. 3 and Tongyi No. 12 due to personal funding needs. On October 21, the reduction was completed, with Tongyi No. 3 and Tongyi No. 12 cumulatively selling 20.666 million shares, representing a reduction ratio of 0.53%.
Core Business Under Pressure; External M&A Hits a Wall
When the company went public through a reverse merger in 2015, Meinian Onehealth told a story of "M&A expansion plus economies of scale," rapidly rolling out nationwide clinics through continuous acquisitions, leveraging its leading position to enhance pricing power, and ultimately achieving dual growth in revenue and profit. This narrative supported a market value of tens of billions of yuan before 2019, but as industry conditions changed and post-merger side effects emerged, the story gradually lost its appeal.
After 2020, the company's revenue growth slowed, with negative growth in the most recent three reporting periods. On the profit side, net profit has been highly volatile in recent years, with the company falling back into losses in the first half of 2026.
Meanwhile, in July 2026, the external growth path suffered its first setback. On July 24, the Shenzhen Stock Exchange officially issued a decision to terminate the review of the application for share issuance to purchase assets by Meinian Onehealth, as the company voluntarily withdrew its application documents, formally ending the review of the share issuance for asset acquisition and related-party transaction. The company had originally planned to acquire equity stakes in 11 associate companies including Hengyang Meinian and Ningde Meinian, as well as minority stakes in five controlled subsidiaries including Zhengzhou Meijian, totaling 16 health examination center assets, with a transaction consideration of 428 million yuan.
According to previously disclosed appraisal reports, multiple of the 16 target companies showed declining net profits, with the appreciation rates under the income approach generally exceeding 200%, and Yantai Meinian's appreciation rate reaching as high as 1,626.55%.
When the growth story can no longer continue, the market can only anchor pricing to existing operations. From a financial perspective, in the first three quarters of 2026, the company's revenue is expected to be approximately 6.51 billion yuan to 6.65 billion yuan, down about 3.98% to 6% year-on-year. Net profit attributable to shareholders is projected at 91 million yuan to 100 million yuan, up 75.47% to 92.83% year-on-year.
It is worth noting that the company's profit recovery may mainly stem from cost compression. Based on interim report data, from the first half of 2024 to the first half of 2026, the company's total period expenses were 1.672 billion yuan, 1.573 billion yuan, and 1.474 billion yuan, respectively, shrinking by approximately 100 million yuan per year on average.
In terms of operations, the company's total customer visits in the first half of 2026 were 9.25 million, down 3.1% year-on-year, with controlled clinics receiving 5.75 million visits, down 4.2% year-on-year. In terms of average spending per customer, the figure was 628 yuan in the first half of 2026, down 4.3% year-on-year. Overall, the business showed a trend of declining volumes and prices.
This has also led to sustained pressure on gross margin, which fell to 33.9% in the first half of 2026, a historic low for the same period and the fourth consecutive year of interim declines. From an operating metrics perspective, over the past three interim reports, the company's operating cycle and accounts receivable turnover days have continued to lengthen, reaching 151.77 days and 139.48 days respectively in the first half of 2026, both hitting record highs.
In 2024, the company made provisions for bad debts on accounts receivable of 136 million yuan, and in 2025, it provisioned 130 million yuan, with provisions exceeding 130 million yuan for two consecutive years. Additionally, the company's long-standing high goodwill remains elevated. As of the end of June 2026, the book value of goodwill was still as high as 5.193 billion yuan, accounting for more than 40% of net assets at period-end. Against the backdrop of a weak core business, subsequent impairment pressure remains a concern.
Comments